Get the Stockscreener App
36.58
0.30%
0.11
After Hours:
36.58
Anaptysbio Inc stock is traded at $36.58, with a volume of 229.87K.
It is up +0.30% in the last 24 hours and up +19.46% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$36.47
Open:
$36.4
24h Volume:
229.87K
Relative Volume:
0.45
Market Cap:
$1.02B
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-6.0164
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
+4.31%
1M Performance:
+19.46%
6M Performance:
+64.63%
1Y Performance:
+69.12%
1-Day Range:
$36.03
$36.96
1-Week Range:
$35.05
$38.38
52-Week Range:
$12.21
$38.38
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
36.58 | 1.02B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
How currency fluctuations impact AnaptysBio Inc. stock2025 Year in Review & Stock Portfolio Risk Control - newser.com
How rising interest rates impact AnaptysBio Inc. stockQuarterly Performance Summary & AI Powered Buy and Sell Recommendations - newser.com
Can AnaptysBio Inc. stock weather global recession2025 Volume Leaders & High Conviction Investment Ideas - newser.com
Does AnaptysBio Inc. show high probability of reboundRisk Management & Long-Term Safe Investment Ideas - newser.com
Using fundamentals and technicals on AnaptysBio Inc.Gap Up & Stepwise Trade Execution Plans - newser.com
Real time alert setup for AnaptysBio Inc. performanceVolume Spike & Reliable Entry Point Alerts - newser.com
What drives AnaptysBio Inc AN6 stock pricePrice Support Zones & Free Unlock Stock Analysis - earlytimes.in
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Can AnaptysBio Inc. stock beat market expectations this quarterQuarterly Portfolio Report & Technical Confirmation Alerts - newser.com
AnaptysBio FY2025 EPS Estimate Boosted by Leerink Partnrs - MarketBeat
A Look at AnaptysBio's (ANAB) Valuation Following Promising Phase 2b Rosnilimab Results and Analyst Upgrades - Yahoo Finance
Moody Aldrich Partners LLC Sells 23,130 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
Is AnaptysBio Inc. (AN6) stock worth holding before Fed meeting2025 Price Momentum & Free Growth Oriented Trading Recommendations - newser.com
Why AnaptysBio Inc. stock is recommended by analystsPortfolio Risk Report & Intraday High Probability Alerts - newser.com
Is AnaptysBio Inc. stock positioned well for digital economyPortfolio Update Report & Stepwise Entry/Exit Trade Alerts - newser.com
Risk adjusted return profile for AnaptysBio Inc. analyzedQuarterly Market Review & Momentum Based Trading Signals - newser.com
Applying big data sentiment scoring on AnaptysBio Inc.Market Activity Recap & Weekly Sector Rotation Insights - newser.com
How AnaptysBio Inc. stock reacts to job market data2025 Short Interest & Daily Technical Stock Forecast Reports - newser.com
Published on: 2025-10-31 05:16:43 - newser.com
Why AnaptysBio Inc. (AN6) stock could be top winnerTrade Performance Summary & Detailed Earnings Play Alerts - newser.com
Will AnaptysBio Inc. (AN6) stock outperform benchmarksNew Guidance & Verified Trade Idea Suggestions - newser.com
Can AnaptysBio Inc. stock sustain revenue growthTrade Volume Summary & Low Volatility Stock Suggestions - newser.com
Identifying reversal signals in AnaptysBio Inc.Swing Trade & Weekly Hot Stock Watchlists - newser.com
How AnaptysBio Inc. stock benefits from tech adoption2025 Big Picture & Real-Time Volume Surge Alerts - newser.com
Published on: 2025-10-31 00:12:04 - newser.com
Will AnaptysBio Inc. stock benefit from sector rotation2025 Breakouts & Breakdowns & Safe Entry Zone Tips - newser.com
What analysts say about AnaptysBio Inc stockInsider Trading Compliance & Small Budget Trading Portfolio - earlytimes.in
AnaptysBio, Inc. Hits New 52-Week High at $38.38 - Markets Mojo
AnaptysBio (ANAB): Assessing Valuation After Robust Phase 2b Rosnilimab Rheumatoid Arthritis Trial Results - Sahm
Published on: 2025-10-30 00:32:17 - newser.com
Stifel Raises Price Target for AnaptysBio (ANAB) to $80 | ANAB S - GuruFocus
AnaptysBio stock rises after positive rheumatoid arthritis trial data By Investing.com - Investing.com Philippines
AnaptysBio stock rises after positive rheumatoid arthritis trial data - Investing.com
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):